Prospective Registry of Multiplex Testing (PROMPT)

This study is being done to learn more about how changes in certain genes may be linked to cancer. Some people with cancer got their disease because they inherited an abnormal (mutated) gene.

The researchers of this study want to better understand the risks that are linked to genetic changes in these less well-studied genes. By understanding these risks, we believe that doctors will be able to give better advice to families with mutations in these genes.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Genetic Testing

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dana Farber Cancer Institute, Boston, Massachusetts, United States

About this study

PROMPT (Prospective Registry of Multiplex Testing) is an Internet-based, patient-directed ascertainment study. It is a partnership between Memorial Sloan Kettering, University of Pennsylvania, Mayo Clinic, and Dana Farber Cancer Institute in collaboration with Ambry Genetics, GeneDx, Myriad Genetics, Pathway Genomics, and Quest Laboratories (5 laboratories providing multiplex panel testing commercially).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Individual with deleterious (pathogenic) or likely deleterious (likely pathogenic) mutation in a cancer susceptibility gene OR
Individual with a variant of uncertain significance (VUS) in a cancer susceptibility gene OR
Family members, either tested or not tested, who are part of a family known to be transmitting a deleterious or likely deleterious mutation or a variant of uncertain significance in a cancer predisposition gene

Exclusion criteria

Inability or refusal to participate in consent discussion
Subject is less than 18 years old

Treatment and study plan

saliva specimen

Other

Questionnaire

Behavioral

Primary outcomes

Acquire DNA samples

Time frame: 3 years
Acquire pathology materials

Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Collaborators

Dana-Farber Cancer Institute
Mayo Clinic
University of Pennsylvania

Registry information

Official study title

Prospective Registry of Multiplex Testing (PROMPT): Phase II

Important dates

Study start: 2016
Primary completion: 2027
Study completion: 2027
First posted: Jan 27, 2016
Registry last updated: Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting